GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (FRA:1VT) » Definitions » Total Debt per Share

Viking Therapeutics (FRA:1VT) Total Debt per Share : €0.01 (As of Dec. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Viking Therapeutics Total Debt per Share?

€0.01 (As of Dec. 2024)

Total Debt per Share is calculated as total debt divided by Shares Outstanding (EOP). Total debt is calculated as Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. Viking Therapeutics's Total Debt Per Share for the quarter that ended in Dec. 2024 was €0.01.

Viking Therapeutics Total Debt per Share Historical Data

The historical data trend for Viking Therapeutics's Total Debt per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Viking Therapeutics Total Debt per Share Chart

Viking Therapeutics Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Total Debt per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.02 0.01 0.01

Viking Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Total Debt per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 0.01 0.01 0.01

Viking Therapeutics Total Debt per Share Calculation

Viking Therapeutics's Total Debt Per Share for the fiscal year that ended in Dec. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.60+0.47)/111.57
=0.01

Viking Therapeutics's Total Debt Per Share for the quarter that ended in Dec. 2024 is calculated as:

Total Debt Per Share=(Long-Term Debt & Capital Lease Obligation+Short-Term Debt & Capital Lease Obligation)/Shares Outstanding (EOP)
=(0.60+0.47)/111.57
=0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Viking Therapeutics Total Debt per Share Related Terms

Thank you for viewing the detailed overview of Viking Therapeutics's Total Debt per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Viking Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Viking Therapeutics Inc (FRA:1VT) » Definitions » Total Debt per Share
Comparable Companies
ADMA ZLAB BHVN RNA PTCT RARE AKRO RXRX IMVT SRRK VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX XBRU:UCB ALNY ONC BNTX XKRX:068270
Traded in Other Exchanges
VKTX:USA 0VQA:UK
Address
9920 Pacific Heights Boulevard, Suite 350, San Diego, CA, USA, 92121
Website
https://www.vikingtherapeutics.com
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Viking Therapeutics Headlines

No Headlines